CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$24.69
-0.13 (-0.52%)
▼
5d:
+1.81%
30d:
+0.0%
90d:
+5.78%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 06, 2026
30d
Smart Money Distribution
CPRX is up 8.6% this week, but smart money is buying puts. Top strike: $20 2026-06-18 with 1,291 OI. Put ratio: 79% View Scanner →
Strength: 7.2/10
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CPRX shows positive signals but monitor for confirmation. Market pricing in 3.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CPRX shows positive signals but monitor for confirmation. Market pricing in 3.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.80
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$23.47
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $24.69, which is considered extended relative to its 30-day fair value range of $23.15 to $24.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.9) compared to its historical average (8.8). Remarkably, the market is currently pricing in an annual earnings decline of 3.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CPRX is in a strong downtrend. The price is approaching resistance at $25.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.00 (+37.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CPRX is in a strong downtrend. The price is approaching resistance at $25.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.00 (+37.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$23.15 -
$24.60
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 37.7% below Wall St target ($34.00)
Fair Price Analysis
30-Day Fair Range
$23.15 -
$24.60
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$22.16
Resistance Level
$25.14
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.92
Wall Street Target
$34.00
(+37.7%)
Revenue Growth (YoY)
7.6%
Earnings Growth (YoY)
-6.4%
Profit Margin
36.4%
Valuation Discount vs History
-3.3% cheaper
PE vs Historical
7.9 vs 8.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.3%
(market-implied from PE analysis)
1-Year Target
$23.88
(-3%)
2-Year Target
$23.09
(-7%)
3-Year Target
$22.33
(-10%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$24.79
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 9.3%)
$83.58
(+239%)
Base:
(SPY PE: 7.9, Growth: 9.3%)
$32.20
(+30%)
Bear:
(PE: 6.7, Growth: 9.3%)
$27.37
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 13.57 | Current EPS (TTM): $1.68
Bull Case
$46.49
(+99%)
Analyst growth 85.4%, PE expands to 14.9
Base Case
$42.26
(+81%)
Market implied 85.4%, PE stable at 13.6
Bear Case
$15.50
(-34%)
Severe decline -20.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.9 to 8.8
Stabilization Target:
$27.42
(+11.0%)
PE Expansion Potential:
+11.0%
Share & Embed Analysis
Last updated: April 05, 2026 6:14 PM ET
Data refreshes hourly during market hours. Next update: 7:14 PM
Data refreshes hourly during market hours. Next update: 7:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Molly Harper
SELL
26746 shares
2025-12-12
Carmen Jeffrey Del
SELL
10983 shares
2025-11-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
